SOAP Note for ACE Inhibitor-Induced Angioedema
Subjective
Chief Complaint: Swollen tongue with throat tightness
History of Present Illness: Patient reports acute onset of anterior tongue swelling accompanied by mild dysphonia and throat tightness. Recently started on an ACE inhibitor. Denies drooling, vomiting, urticaria, or difficulty breathing. No prior episodes of angioedema. No history of asthma or atopic disease.
Medications: ACE inhibitor (recently initiated)
Allergies: None reported
Past Medical History: Likely hypertension (given ACE inhibitor use)
Family History: No family history of angioedema
Objective
Vital Signs:
- Blood pressure: Normal
- Heart rate: Mildly elevated (tachycardia)
- Respiratory rate: Normal
- Oxygen saturation: Normal
- Temperature: Afebrile
Physical Examination:
- General: Alert, no acute distress
- HEENT: Visible swelling of anterior two-thirds of tongue, no drooling
- Oropharynx: Patent airway, assess for posterior pharyngeal wall swelling
- Neck: Assess for laryngeal involvement
- Skin: No urticaria, no erythema marginatum
- Respiratory: Clear breath sounds bilaterally, no stridor, no wheezing
- Cardiovascular: Tachycardic, regular rhythm
Assessment
Primary Diagnosis: ACE inhibitor-induced angioedema 1
Differential Diagnoses:
- Hereditary angioedema (HAE) - less likely given no family history and recent ACE inhibitor initiation
- Allergic angioedema - unlikely given absence of urticaria
- Idiopathic angioedema
Rationale: This presentation is consistent with drug-induced angioedema (AE-DI) secondary to ACE inhibitor use 1. ACE inhibitors cause angioedema through bradykinin accumulation, as ACE (kininase II) normally degrades bradykinin 1. This can occur at any time during therapy, even years after initiation 2, 3, 4. The absence of urticaria, recent ACE inhibitor initiation, and clinical presentation strongly support this diagnosis.
Critical Assessment Points:
- Airway patency is the primary concern - monitor closely for signs of laryngeal involvement including voice changes, inability to swallow, and respiratory distress 5
- Standard angioedema treatments (epinephrine, corticosteroids, antihistamines) are NOT effective for bradykinin-mediated angioedema 5
- This patient requires observation in a facility capable of emergency airway management 5
Plan
Immediate Management
1. Airway Monitoring (CRITICAL):
- Admit for observation in a setting with immediate access to intubation/tracheostomy capabilities 5
- Monitor continuously for signs of airway compromise: voice changes, loss of ability to swallow, difficulty breathing 5
- Consider flexible nasoendoscopy to assess laryngeal involvement 3
2. Discontinue ACE Inhibitor IMMEDIATELY:
- Stop the ACE inhibitor permanently 1, 2
- Document allergy in medical record
- Avoid all ACE inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), and consider avoiding dipeptidyl peptidase IV (DPPIV) inhibitors 1
3. Pharmacologic Treatment:
First-line options for acute bradykinin-mediated angioedema:
- Icatibant (bradykinin B2 receptor antagonist) - one study showed more rapid symptom improvement compared to corticosteroids/antihistamines 6, though evidence is mixed 1
- C1 esterase inhibitor concentrate - can be effective in severe cases 3
- Ecallantide (plasma kallikrein inhibitor) - available but evidence for benefit in ACE inhibitor-induced angioedema is limited 6
Supportive care (may provide temporary benefit but not definitive):
- Fresh frozen plasma - can be effective but may paradoxically worsen symptoms in some cases; use with caution 5
- Epinephrine - may provide temporary vasoconstriction but does not change overall attack course 5
- Corticosteroids and antihistamines - NOT effective for bradykinin-mediated angioedema but commonly given 5, 6
4. Symptomatic Management:
- NPO status until swelling resolves
- IV hydration
- Supplemental oxygen if needed
Disposition
- Admit for minimum 24 hours of observation given oropharyngeal involvement 5
- Discharge only after complete resolution of swelling and confirmed airway patency
- Consider repeat nasoendoscopy before discharge if initial examination showed laryngeal involvement 3
Follow-up and Prevention
Patient Education:
- Explain that symptoms may recur for 1-2 episodes after discontinuation but should resolve completely 2
- Typical attack progression: worsens over 24 hours, then slowly remits over 48-72 hours 5
- Instruct to return immediately for any recurrence, especially with throat involvement
Medication Management:
- Switch to alternative antihypertensive (angiotensin receptor blocker may be considered, though cross-reactivity is possible)
- Document ACE inhibitor allergy prominently in medical record
- Avoid NSAIDs and tissue plasminogen activators which can also trigger angioedema 1
Laboratory Workup (if diagnosis uncertain):
- C4 level and C1 inhibitor level/function to rule out hereditary angioedema - though clinical presentation makes this unlikely 5
Common Pitfalls to Avoid
- Do NOT rely on epinephrine, corticosteroids, or antihistamines as primary treatment - these are ineffective for bradykinin-mediated angioedema 5
- Do NOT discharge without adequate observation period - laryngeal attacks can be fatal 5
- Do NOT restart ACE inhibitor - angioedema can recur even years later 2, 3, 4
- Do NOT assume early onset is required - ACE inhibitor-induced angioedema can occur after years of uneventful therapy 2, 3, 4